NASDAQ : BIVI
BioVie Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.43 USD (Oct 30, 2026, 3:25 PM EDT) · Market cap 10.79M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year July - June; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 8.51M | 8.51M | 8.57M | 8.85M | 11.55M | 9.77M |
| Research & Development | 13.96M | 13.96M | 9.27M | 23.10M | 33.30M | 17.26M |
| Amortization of Goodwill & Intangibles | 178.34K | 178.34K | 229.38K | 229.38K | 229.38K | 229.38K |
| Operating Expenses | 22.65M | 22.65M | 18.07M | 32.18M | 45.08M | 27.25M |
| Operating Income | -22.65M | -22.65M | -18.07M | -32.18M | -45.08M | -27.25M |
| Interest Expense | -17.90K | -17.90K | -332.72K | -2.89M | -4.30M | -2.16M |
| Interest & Investment Income | 596.77K | 596.77K | 853.03K | 1.14M | 562.26K | 44.08K |
| Other Non Operating Income (Expenses) | 3.77K | 1.82M | -1.44M | 3.29M | ||
| EBT Excluding Unusual Items | -22.07M | -22.07M | -17.54M | -32.12M | -50.26M | -26.08M |
| Pretax Income | -22.07M | -22.07M | -17.54M | -32.12M | -50.26M | -26.08M |
| Net Income | -22.07M | -22.07M | -17.54M | -32.12M | -50.26M | -26.08M |
| Preferred Dividends & Other Adjustments | 43.54K | 43.54K | 369.46K | 886.42K | ||
| Net Income to Common | -22.12M | -22.12M | -17.91M | -33.01M | -50.26M | -26.08M |
| Shares Outstanding (Basic) | 7.25M | 7.25M | 1.48M | 451.85K | 324.83K | 246.63K |
| Shares Outstanding (Diluted) | 7.25M | 7.25M | 1.48M | 451.85K | 324.83K | 246.63K |
| EPS (Basic) | -3.05 | -3.05 | -12.12 | -73.05 | -154.71 | -105.77 |
| EPS (Diluted) | -3.05 | -3.05 | -12.12 | -73.05 | -154.71 | -106.00 |
| EBITDA | -22.47M | -22.47M | -17.84M | -31.95M | -44.85M | -27.02M |
| D&A For EBITDA | 178.34K | 178.34K | 229.38K | 229.38K | 229.38K | 229.38K |
| EBIT | -22.65M | -22.65M | -18.07M | -32.18M | -45.08M | -27.25M |
Balance sheet
Fiscal year July - June; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.98M | 8.98M | 17.54M | 23.84M | 19.46M | 18.64M |
| Short-Term Investments | 14.48M | |||||
| Cash & Short-Term Investments | 8.98M | 8.98M | 17.54M | 23.84M | 33.94M | 18.64M |
| Receivables | 2.15M | 2.15M | 2.10M | |||
| Prepaid Expenses | 2.51M | 2.51M | 1.05M | 204.39K | 102.53K | 137.88K |
| Total Current Assets | 13.64M | 13.64M | 20.70M | 24.05M | 34.04M | 18.78M |
| Property, Plant & Equipment | 262.59K | 262.59K | 339.65K | 406.73K | 80.79K | 118.25K |
| Goodwill | 345.71K | 345.71K | 345.71K | 345.71K | 345.71K | 345.71K |
| Other Intangible Assets | 178.34K | 407.72K | 637.10K | 866.47K | ||
| Other Long-Term Assets | 4.56K | |||||
| Total Assets | 14.25M | 14.25M | 21.56M | 25.21M | 35.10M | 20.11M |
| Accounts Payable | 3.70M | 3.70M | 2.20M | 3.59M | 3.48M | 2.44M |
| Accrued Expenses | 48.38K | 580.61K | ||||
| Current Portion of Long-Term Debt | 5.70M | 9.11M | ||||
| Current Portion of Leases | 91.01K | 91.01K | 74.46K | 60.34K | 44.91K | 38.88K |
| Other Current Liabilities | 3.77K | 1.82M | 1.11M | |||
| Total Current Liabilities | 3.80M | 3.80M | 2.27M | 9.35M | 14.49M | 4.17M |
| Long-Term Debt | 5.23M | 12.14M | ||||
| Long-Term Leases | 184.42K | 184.42K | 275.43K | 349.89K | 42.51K | 87.41K |
| Other Long-Term Liabilities | 48.38K | |||||
| Total Liabilities | 3.98M | 3.98M | 2.55M | 9.70M | 19.76M | 16.44M |
| Common Stock | 754.00 | 754.00 | 192.00 | 6.23K | 3.64K | 2.50K |
| Additional Paid-In Capital | 384.53M | 384.53M | 371.16M | 349.73M | 316.39M | 254.64M |
| Retained Earnings | -374.26M | -374.26M | -352.14M | -334.23M | -301.23M | -250.97M |
| Treasury Stock | -29.00 | -29.00 | -29.00 | -27.00 | -2.00 | |
| Comprehensive Income & Other | 176.59K | |||||
| Shareholders' Equity | 10.27M | 10.27M | 19.01M | 15.51M | 15.34M | 3.67M |
| Total Liabilities & Equity | 14.25M | 14.25M | 21.56M | 25.21M | 35.10M | 20.11M |
| Total Debt | 275.43K | 275.43K | 349.89K | 6.11M | 14.42M | 12.26M |
| Net Cash (Debt) | 8.70M | 8.70M | 17.19M | 17.73M | 19.52M | 6.38M |
| Net Cash Per Share | 1.20 | 1.20 | 11.64 | 39.24 | 60.09 | 25.86 |
| Filing Date Shares Outstanding | 7.54M | 7.54M | 7.53M | 793.03K | 367.81K | 301.65K |
| Total Common Shares Outstanding | 7.54M | 7.54M | 1.91M | 619.01K | 364.29K | 249.84K |
| Working Capital | 9.85M | 9.85M | 18.42M | 14.70M | 19.55M | 14.61M |
| Book Value Per Share | 1.36 | 1.36 | 9.93 | 25.05 | 42.11 | 14.69 |
| Tangible Book Value | 9.92M | 9.92M | 18.49M | 14.75M | 14.36M | 2.46M |
| Tangible Book Value Per Share | 1.32 | 1.32 | 9.66 | 23.83 | 39.41 | 9.84 |
Cash flow statement
Fiscal year July - June; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -22.07M | -22.07M | -17.54M | -32.12M | -50.26M | -26.08M |
| Depreciation & Amortization | 178.34K | 178.34K | 229.38K | 229.38K | 229.38K | 229.38K |
| Other Amortization | 11.82K | 108.75K | 170.22K | 99.30K | ||
| Loss (Gain) From Sale of Investments | -223.87K | |||||
| Stock-Based Compensation | 2.87M | 2.87M | 2.47M | 4.66M | 6.38M | 6.19M |
| Other Operating Activities | 77.07K | 77.07K | 200.27K | -512.02K | 3.50M | -2.18M |
| Change in Accounts Receivable | -47.39K | -47.39K | -2.10M | |||
| Change in Accounts Payable | 1.50M | 1.50M | -1.39M | 110.65K | 1.03M | 1.45M |
| Change in Other Net Operating Assets | -1.54M | -1.54M | -905.85K | -197.50K | -1.30M | 1.30M |
| Operating Cash Flow | -19.02M | -19.02M | -19.03M | -27.95M | -40.25M | -18.99M |
| Investment in Securities | 14.53M | -14.30M | ||||
| Investing Cash Flow | 14.53M | -14.30M | ||||
| Long-Term Debt Issued | 14.61M | |||||
| Total Debt Issued | 14.61M | |||||
| Long-Term Debt Repaid | -5.85M | |||||
| Total Debt Repaid | -5.85M | |||||
| Net Debt Issued (Repaid) | -5.85M | 14.61M | ||||
| Issuance of Common Stock | 10.46M | 10.46M | 18.58M | 27.80M | 55.37M | 18.51M |
| Other Financing Activities | -10.00M | |||||
| Financing Cash Flow | 10.46M | 10.46M | 12.73M | 17.80M | 55.37M | 33.12M |
| Net Cash Flow | -8.57M | -8.57M | -6.30M | 4.38M | 819.17K | 14.13M |
| Levered Free Cash Flow | -11.12M | -11.12M | -13.13M | -18.78M | -22.84M | -8.77M |
| Unlevered Free Cash Flow | -11.11M | -11.11M | -12.93M | -17.08M | -20.32M | -7.52M |
| Cash Interest Paid | 17.90K | 17.90K | 183.93K | 1.53M | 2.11M | 964.24K |
| Change in Working Capital | -80.87K | -80.87K | -4.40M | -86.84K | -270.44K | 2.75M |
Ratios
Fiscal year July - June; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 10.22M | 14.63M | 17.15M | 24.48M | 156.37M | 36.23M |
| Enterprise Value | 1.52M | 1.83M | -5.63M | 2.54M | 126.47M | 23.47M |
| Last Close Price | 1.43 | 1.94 | 9.25 | 40.05 | 431.00 | 145.00 |
| PB Ratio | 1.05 | 1.43 | 0.90 | 1.58 | 10.19 | 9.87 |
| P/TBV Ratio | 1.02 | 1.47 | 0.93 | 1.66 | 10.89 | 14.73 |
| Debt / Equity Ratio | 0.03 | 0.03 | 0.02 | 0.39 | 0.94 | 3.34 |
| Net Debt / Equity Ratio | -0.85 | -0.85 | -0.90 | -1.14 | -1.27 | -1.74 |
| Net Debt / EBITDA Ratio | 0.39 | 0.39 | 0.96 | 0.56 | 0.43 | 0.24 |
| Quick Ratio | 2.93 | 2.93 | 8.64 | 2.55 | 2.34 | 4.47 |
| Current Ratio | 3.59 | 3.59 | 9.10 | 2.57 | 2.35 | 4.50 |
| Return on Equity (ROE) | -150.76% | -150.76% | -101.64% | -208.26% | -528.70% | -598.18% |
| Return on Assets (ROA) | -79.06% | -79.06% | -48.28% | -66.69% | -102.05% | -130.22% |
| Return on Capital Employed (ROCE) | -216.70% | -216.70% | -93.70% | -202.90% | -218.70% | -170.90% |
| Earnings Yield | -225.26% | -150.86% | -102.28% | -131.23% | -32.14% | -72.00% |
| Buyback Yield / Dilution | -390.46% | -390.46% | -226.96% | -39.10% | -31.71% | -98.84% |